UA78259C2 - Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i) - Google Patents

Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i) Download PDF

Info

Publication number
UA78259C2
UA78259C2 UA20040705367A UA20040705367A UA78259C2 UA 78259 C2 UA78259 C2 UA 78259C2 UA 20040705367 A UA20040705367 A UA 20040705367A UA 20040705367 A UA20040705367 A UA 20040705367A UA 78259 C2 UA78259 C2 UA 78259C2
Authority
UA
Ukraine
Prior art keywords
pyrimidine
ylamino
pharmaceutically acceptable
pyrazol
compound
Prior art date
Application number
UA20040705367A
Other languages
English (en)
Ukrainian (uk)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of UA78259C2 publication Critical patent/UA78259C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UA20040705367A 2001-12-07 2002-03-12 Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i) UA78259C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0104140A SE0104140D0 (sv) 2001-12-07 2001-12-07 Novel Compounds
PCT/SE2002/002221 WO2003048133A1 (en) 2001-12-07 2002-12-03 Pyrimidine derivatives as modulators of insuline-like growth factor-1 receptor (igf-i)

Publications (1)

Publication Number Publication Date
UA78259C2 true UA78259C2 (en) 2007-03-15

Family

ID=20286257

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20040705367A UA78259C2 (en) 2001-12-07 2002-03-12 Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i)

Country Status (33)

Country Link
US (3) US7521453B2 (ko)
EP (1) EP1456182B1 (ko)
JP (1) JP4347051B2 (ko)
KR (1) KR100930558B1 (ko)
CN (1) CN1289486C (ko)
AR (1) AR037736A1 (ko)
AT (1) ATE425150T1 (ko)
AU (1) AU2002365864B2 (ko)
BR (1) BR0214605A (ko)
CA (1) CA2467838C (ko)
CO (1) CO5590919A2 (ko)
CY (1) CY1109101T1 (ko)
DE (1) DE60231542D1 (ko)
DK (1) DK1456182T3 (ko)
EG (1) EG24930A (ko)
ES (1) ES2323125T3 (ko)
HK (1) HK1067631A1 (ko)
HU (1) HUP0401855A3 (ko)
IL (2) IL162376A0 (ko)
IS (1) IS7294A (ko)
MX (1) MXPA04005347A (ko)
MY (1) MY135705A (ko)
NO (1) NO327502B1 (ko)
NZ (1) NZ533130A (ko)
PL (1) PL369528A1 (ko)
PT (1) PT1456182E (ko)
RU (1) RU2317291C2 (ko)
SE (1) SE0104140D0 (ko)
SI (1) SI1456182T1 (ko)
TW (1) TWI324152B (ko)
UA (1) UA78259C2 (ko)
WO (1) WO2003048133A1 (ko)
ZA (1) ZA200404223B (ko)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ATE451104T1 (de) 2002-07-29 2009-12-15 Rigel Pharmaceuticals Inc Verfahren zur behandlung oder pruvention von autoimmunkrankheiten mit 2,4-pyrimidindiamin- verbindungen
US7504396B2 (en) 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
US7442698B2 (en) 2003-07-24 2008-10-28 Amgen Inc. Substituted heterocyclic compounds and methods of use
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
US20050113398A1 (en) * 2003-08-07 2005-05-26 Ankush Argade 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
WO2005037836A2 (en) * 2003-10-15 2005-04-28 Osi Pharmaceuticals, Inc. Imidazo ‘1, 5 - a ! pyrazine tyrosine kinase inhibitors
DE602004022187D1 (de) 2003-10-17 2009-09-03 Astrazeneca Ab 4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
SI1732898T1 (sl) 2004-03-12 2008-06-30 Analytecon Sa Tetrahidroizokinolinski in tetrahidrobenzazepinski derivati kot inhibitorji IGF-1R
EP1730128A1 (en) * 2004-03-31 2006-12-13 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
DK1740591T3 (da) * 2004-04-02 2009-10-26 Osi Pharm Inc Heterobicykliske proteinkinaseinhibitorer substitueret med en 6,6-biocyclisk ring
DE102004022897A1 (de) * 2004-05-10 2005-12-08 Bayer Cropscience Ag Azinyl-imidazoazine
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
ES2375735T3 (es) 2005-02-04 2012-03-05 Astrazeneca Ab Derivados de pirazolilaminopiridina útiles como inhibidores de quinasas.
AU2006215386B2 (en) 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
GB0507347D0 (en) * 2005-04-12 2005-05-18 Astrazeneca Ab Chemical compounds
CN101208093A (zh) * 2005-04-27 2008-06-25 阿斯利康(瑞典)有限公司 吡唑-嘧啶衍生物在治疗疼痛中的用途
BRPI0610184A2 (pt) * 2005-05-16 2012-09-25 Astrazeneca Ab composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7566721B2 (en) * 2005-08-08 2009-07-28 Osi Pharmaceuticals, Inc. Substituted thienol[2,3-d]pyrimidines as kinase inhibitors
CA2620174A1 (en) 2005-08-24 2007-03-01 Wyeth Bazedoxifene acetate formulations and manufacturing process thereof
WO2007035744A1 (en) 2005-09-20 2007-03-29 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2388259A1 (en) * 2005-10-28 2011-11-23 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
UA97953C2 (uk) * 2006-06-09 2012-04-10 Новартіс Аг Стабілізовані поліпептиди інсуліноподібного фактора росту
AU2007257701A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-aminoalkyleneaminopyrimidines
TW200817391A (en) * 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
WO2008129255A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab 5-aminopyrazol-3-yl-3h-imidazo [4,5-b] pyridine derivatives and their use for the treatment of cancer
US20100204231A1 (en) * 2007-05-04 2010-08-12 Astrazeneca Ab Amino-thiazolyl-pyrimidine derivatives and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
US8178091B2 (en) 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2009019518A1 (en) * 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
JP2011520970A (ja) * 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
CA2727073A1 (en) * 2008-06-11 2009-12-17 Astrazeneca Ab Tricyclic 2,4-diamin0-l,3,5-triazine derivatives useful for the treatment of cancer and myeloproliferative disorders
DE102008041214A1 (de) 2008-08-13 2010-02-18 Bayer Cropscience Ag N-substituierte Azinylakyl-azincarboxamide und deren Analoge
KR20110071098A (ko) * 2008-09-30 2011-06-28 아스트라제네카 아베 복소환 jak 키나제 억제제
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2400990A2 (en) 2009-02-26 2012-01-04 OSI Pharmaceuticals, LLC In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
MX2011011025A (es) 2009-04-20 2011-11-02 Osi Pharmaceuticals Llc Preparacion de c-piracin-metilaminas.
WO2010129740A1 (en) * 2009-05-07 2010-11-11 Osi Pharmaceuticals, Inc. Use of osi-906 for treating adrenocortical carcinoma
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20110275644A1 (en) 2010-03-03 2011-11-10 Buck Elizabeth A Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CN102970867A (zh) 2010-03-18 2013-03-13 拜耳知识产权有限责任公司 作为活性剂对抗非生物植物应激的芳基和杂芳基磺酰胺
KR20130031296A (ko) 2010-05-21 2013-03-28 케밀리아 에이비 신규한 피리미딘 유도체
US8546443B2 (en) * 2010-12-21 2013-10-01 Boehringer Ingelheim International Gmbh Benzylic oxindole pyrimidines
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
DK2688883T3 (en) 2011-03-24 2016-09-05 Noviga Res Ab pyrimidine
US8729253B2 (en) 2011-04-13 2014-05-20 Eastman Chemical Company Cellulose ester optical films
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013071056A2 (en) 2011-11-11 2013-05-16 Duke University Combination drug therapy for the treatment of solid tumors
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
JP6255038B2 (ja) 2013-02-26 2017-12-27 トリアクト セラピューティクス,インク. 癌治療
EP3044593A4 (en) 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
WO2017129763A1 (en) 2016-01-28 2017-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer
CN115124475B (zh) * 2022-07-11 2023-11-10 贵阳学院 一种嘧啶衍生物及其制备方法和用途
WO2024153237A1 (zh) * 2023-01-19 2024-07-25 北京普祺医药科技股份有限公司 一种igf-1r酪氨酸激酶抑制剂、药物组合物及其用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1417402A (en) * 1972-03-30 1975-12-10 Boots Co Ltd Pharmacologically active anilinobenzothiazoles
DE2426180A1 (de) 1974-05-29 1975-12-18 Bayer Ag Verfahren zum faerben von polyurethankunststoffen
US4485284A (en) * 1982-01-11 1984-11-27 Advanced Moisture Technology, Inc. Apparatus and process for microwave moisture analysis
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CA2104053C (en) * 1992-08-31 1999-04-13 Miguel A. Cacho Automated fluid bed process
WO1997009325A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
EP0970369B1 (de) * 1997-03-27 2001-09-12 Glatt Gmbh Verfahren zum überwachen und/oder steuern und regeln eines granulations-, agglomerations-, instantisierungs-, coating- und trocknungsprozesses in einer wirbelschicht oder einer bewegten schüttung durch bestimmung der produktfeuchte sowie lufttechnischer apparat zur durchführung des verfahrens
US6247246B1 (en) * 1998-05-27 2001-06-19 Denver Instrument Company Microwave moisture analyzer: apparatus and method
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Hiv 복제를 억제하는 피리미딘
WO2000035455A1 (en) 1998-12-15 2000-06-22 Telik, Inc. Heteroaryl-aryl ureas as igf-1 receptor antagonists
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
JP4919566B2 (ja) * 1999-09-24 2012-04-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗ウイルス組成物
US6455525B1 (en) * 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
HUP0301117A3 (en) 2000-02-17 2004-01-28 Amgen Inc Thousand Oaks Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
EP1282607B1 (en) 2000-05-08 2015-11-11 Janssen Pharmaceutica NV Prodrugs of hiv replication inhibiting pyrimidines
JP4105948B2 (ja) 2000-09-15 2008-06-25 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
KR100909665B1 (ko) 2000-12-21 2009-07-29 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피라졸 화합물 및 이를 포함하는 약제학적 조성물
JP4357295B2 (ja) * 2001-08-03 2009-11-04 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターとその使用
WO2003011854A1 (en) * 2001-08-03 2003-02-13 Vertex Pharmaceuticals Incorporated Pyrazole-derived kinase inhibitors and uses thereof
US6747461B2 (en) * 2001-10-25 2004-06-08 Pioneer Hi-Bred International, Inc. Apparatus and method for monitoring drying of an agricultural porous medium such as grain or seed
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
CA2586375A1 (en) * 2004-11-04 2006-05-18 Juan-Miguel Jimenez Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
AU2006215386B2 (en) * 2005-02-16 2009-06-11 Astrazeneca Ab Chemical compounds
ES2533241T3 (es) * 2005-11-03 2015-04-08 Vertex Pharmaceuticals Incorporated Aminopirimidinas útiles como inhibidores de cinasas
TW200817391A (en) * 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) * 2006-11-01 2008-06-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
EP1456182A1 (en) 2004-09-15
IL162376A0 (en) 2005-11-20
AU2002365864B2 (en) 2007-08-30
KR100930558B1 (ko) 2009-12-09
TWI324152B (en) 2010-05-01
WO2003048133A1 (en) 2003-06-12
NO327502B1 (no) 2009-07-27
US20050054638A1 (en) 2005-03-10
CA2467838A1 (en) 2003-06-12
CO5590919A2 (es) 2005-12-30
TW200409634A (en) 2004-06-16
MXPA04005347A (es) 2004-09-27
ZA200404223B (en) 2005-08-29
MY135705A (en) 2008-06-30
EG24930A (en) 2011-01-11
NO20042872L (no) 2004-07-06
NZ533130A (en) 2006-11-30
SI1456182T1 (sl) 2009-08-31
KR20050044698A (ko) 2005-05-12
CA2467838C (en) 2010-10-12
JP4347051B2 (ja) 2009-10-21
AR037736A1 (es) 2004-12-01
HUP0401855A2 (hu) 2004-12-28
US7521453B2 (en) 2009-04-21
RU2004121029A (ru) 2006-01-10
EP1456182B1 (en) 2009-03-11
BR0214605A (pt) 2004-09-14
CN1617858A (zh) 2005-05-18
DE60231542D1 (de) 2009-04-23
ES2323125T3 (es) 2009-07-07
HUP0401855A3 (en) 2008-06-30
US20120095011A1 (en) 2012-04-19
IL162376A (en) 2011-07-31
US20090131463A1 (en) 2009-05-21
SE0104140D0 (sv) 2001-12-07
JP2005515998A (ja) 2005-06-02
PL369528A1 (en) 2005-05-02
CN1289486C (zh) 2006-12-13
RU2317291C2 (ru) 2008-02-20
IS7294A (is) 2004-06-03
DK1456182T3 (da) 2009-06-29
CY1109101T1 (el) 2014-07-02
AU2002365864A1 (en) 2003-06-17
HK1067631A1 (en) 2005-04-15
ATE425150T1 (de) 2009-03-15
PT1456182E (pt) 2009-05-26

Similar Documents

Publication Publication Date Title
UA78259C2 (en) Pyrimidine derivatives, application thereof, process for preparation (variants) thereof, pharmaceutical compositions, process for preparing pharmaceutical compositions, method for treating cancer, and method for modulating activity of receptor of insuline-like growth factor (igf-i)
AU2022259742B2 (en) Human plasma kallikrein inhibitors
CN101857573A (zh) 取代的喹唑啉衍生物及其作为酪氨酸激酶抑制剂的用途
ES2262137T3 (es) Derivados de pirimidinamina farmacologicamente activos y procedimientos para su preparacion.
CN109952300B (zh) 5或8-取代的咪唑并[1,5-a]吡啶
UA128453C2 (uk) Гетероциклічні сполуки як імуномодулятори
JP2021501123A (ja) Egfrおよび/またはher2の阻害剤ならびに使用方法
BR112015003004B1 (pt) Análogos de piridazina 1,4-dissubstituída, seus usos, e composição farmacêutica
ES2690790T3 (es) Derivados del ácido heterobutílico butanoico como inhibidores de LTA4H
EA029126B1 (ru) Ингибиторы ido
AU2004281906A1 (en) Acylhydrazone derivatives and their use in the inhibition, regulation and/or modulation of the signal transduction of kinases
UA74206C2 (uk) Імідазоло-5-іл-2-анілінопіримідини як агенти для інгібування проліферації клітин
HUE030364T2 (hu) Glukagonreceptor modulátora
WO2020221038A1 (zh) 苯并噻吩类化合物及其制备方法和用途
TW202128706A (zh) 新型雜環化合物
CN110678456A (zh) 吡唑magl抑制剂
CN115536648B (zh) 一类抑制rna解旋酶dhx33的多环化合物及其应用
WO2022032144A1 (en) Substrate adaptor inhibitors of prmt5 and uses thereof
EP4257587A1 (en) Hydroxamate compound, preparation method therefor and application thereof
WO2021155006A1 (en) Inhibitors of cyclin-dependent kinases and uses thereof
US8546389B2 (en) Viral polymerase inhibitors
WO2022249120A1 (ko) 신규한 벤조인돌론 화합물 및 이를 포함하는 약학적 조성물
TW200800871A (en) Novel catechol derivatives pharmaceutical compositions containing the sane and their uses
WO2016202935A1 (en) Glucose transport inhibitors
TWI670262B (zh) 新穎雜芳基丁酸衍生物